{"id":"W4281936531","doi":"10.1200/jco.2022.40.16_suppl.105","title":"Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Cancer; Phases of clinical research; Internal medicine; Oncology; Population; Response Evaluation Criteria in Solid Tumors; Antibody; Stage (stratigraphy); Clinical trial; Cancer research; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007576654,0.000200045,0.002066095,0.0001434321,0.0002161716,0.00001169036,0.0004372831,0.0003061757,0.001527923],"category_scores_gemma":[0.003919177,0.0001614315,0.0004444231,0.0004930735,0.0006573274,0.0001076389,0.0005434818,0.002719431,0.00001005009],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001154299,"about_ca_system_score_gemma":0.004695378,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001815843,"about_ca_topic_score_gemma":0.0001265033,"domain_scores_codex":[0.9937701,0.00102538,0.003073339,0.0003981363,0.001189983,0.0005430878],"domain_scores_gemma":[0.9927945,0.003669023,0.001874223,0.0004308772,0.0006120173,0.0006193421],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.06468201,0.0024656,0.07475891,0.0002114732,0.0005324127,0.002196904,0.001212629,0.0004135715,0.008665208,0.0001227615,0.01710833,0.8276302],"study_design_scores_gemma":[0.02314761,0.02691392,0.2527313,0.0002668854,0.0001232861,0.0009348489,0.001180689,0.0001052283,0.0001851117,0.0001059075,0.6941483,0.000156931],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9804522,0.003503502,0.00006720963,0.01054121,0.002051009,0.0005184967,0.00004712472,0.00001480239,0.002804476],"genre_scores_gemma":[0.9836107,0.01037084,0.002421713,0.001620163,0.001235289,0.00000953883,0.000009084844,0.00004684232,0.0006757839],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8274733,"threshold_uncertainty_score":0.9995813,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.151673482308748,"score_gpt":0.5658398469977208,"score_spread":0.4141663646889728,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}